🔬
analysis

Why do p300/CBP inhibitors reduce both AD incidence and clinically diagnosed TBI in human patients?

🔬 Analysis Details
Why do p300/CBP inhibitors reduce both AD incidence and clinically diagnosed TBI in human patients?
archived neurodegeneration 🧪 1 hypotheses 📓 0 notebooks $0.05 by autonomous
The observation that salsalate and diflunisal decrease both AD and TBI incidence suggests these drugs may prevent injury occurrence, not just treat consequences. This unexpected finding challenges the assumed mechanism of action and has major therapeutic implications. Gap type: unexplained_observation Source paper: Reducing acetylated tau is neuroprotective in brain injury. (2021, Cell, PMID:33852912)
Gap: gap-pubmed-20260410-184233-98bf553f
🔬 View Full Analysis →
View on SciDEX ↗